Phase 3 development plans for BNT327 and ivonescimab start to diverge.

The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

Party season approaches; but first, conferences.

Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.

A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.

The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.

But could toxicity be holding back filing plans?